CSIMarket
 


Mersana Therapeutics inc   (MRSN)
Other Ticker:  
 
 

MRSN's Revenue Growth by Quarter and Year

Mersana Therapeutics Inc 's Revenue results by quarter and year




MRSN Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 10.70 14.69 0.01
III Quarter September - 7.70 5.57 0.01
II Quarter June - 10.65 4.28 0.01
I Quarter March 9.25 7.80 2.04 0.01
FY   9.25 36.85 26.58 0.04



MRSN Revenue first quarter 2024 Y/Y Growth Comment
Mersana Therapeutics inc reported Revenue increase of 18.53% year on year in the first quarter 2024, to $ 9.25 millions, this is lower than Mersana Therapeutics Inc 's recent average Revenue surge of 18204.45%.

Looking into first quarter 2024 results within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue growth. While Mersana Therapeutics Inc ' s Revenue growth of 18.53% ranks overall at the positon no. 607 in the first quarter 2024.




MRSN Revenue ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - -27.16 % 146800 % 0 %
III Quarter September - 38.24 % 55600 % 0 %
II Quarter June - 148.83 % 42700 % -98.75 %
I Quarter March 18.53 % 282.35 % 20300 % 0 %
FY   - 38.64 % 66350 % -95.18 %

Financial Statements
Mersana Therapeutics Inc 's first quarter 2024 Revenue $ 9.25 millions MRSN's Income Statement
Mersana Therapeutics Inc 's first quarter 2023 Revenue $ 7.80 millions Quarterly MRSN's Income Statement
New: More MRSN's historic Revenue Growth >>


MRSN Revenue (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - 38.96 % 163.73 % 0 %
III Quarter September - -27.7 % 30.14 % 0 %
II Quarter June - 36.54 % 109.8 % 0 %
I Quarter March -13.6 % -46.9 % 20300 % 0 %
FY (Year on Year)   - 38.64 % 66350 % -95.18 %




Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #134
Overall #607

Revenue Y/Y Growth Statistics
High Average Low
146780 % 18204.45 % -98.7 %
(Dec 31 2022)   (Sep 30 2020)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #134
Overall #607
Revenue Y/Y Growth Statistics
High Average Low
146780 % 18204.45 % -98.7 %
(Dec 31 2022)   (Sep 30 2020)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Mersana Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
20260 % 1723.81 % -98.62 %
(Mar 31 2022)  


MRSN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Mersana Therapeutics Inc reported drop in Revenue from the previous quarter by -13.6% to $ 9.25 millions, from $ 10.70 millions released in the previous quarter.

If you look into present shortcoming in the quarter, you suppose to assume, that frequently I. Quarter Revenue appear to be softer in contrast to the quarter before, Kevin Thompson, Healthcare sector contributor said.

Within Major Pharmaceutical Preparations industry 87 other companies have achieved higher Revenue quarter on quarter growth. While Mersana Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 2055.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #88
Healthcare Sector #257
Overall #2055
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #88
Healthcare Sector #257
Overall #2055
Revenue Q/Q Growth Statistics
High Average Low
20260 % 1723.81 % -98.62 %
(Mar 31 2022)  


MRSN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Mersana Therapeutics Inc reported drop in Revenue from the previous quarter by -13.6% to $ 9.25 millions, from $ 10.70 millions achived in the previous reporting period.

But that's not huge issue, as Mersana Therapeutics Inc 's Revenue always seem to plunge in the I. Quarter Kevin Thompson, Healthcare sector contributor told.

Within Major Pharmaceutical Preparations industry 87 other companies have achieved higher Revenue quarter on quarter growth. While Mersana Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 2055.


Mersana Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 38.30 $ 36.86 $ 40.84 $ 38.72 $ 32.35
Y / Y Revenue Growth (TTM) 18.4 % 38.65 % 243.12 % 510.58 % 1464.17 %
Year on Year Revenue Growth Overall Ranking # 7 # 1 # 2 # 4 # 119
Seqeuential Revenue Change (TTM) 3.92 % -9.76 % 5.49 % 19.69 % 21.69 %
Seq. Revenue Growth (TTM) Overall Ranking # 418 # 50 # 266 # 134 # 7




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2024 period, Mersana Therapeutics Inc 's cumulative twelve months Revenue were $ 38 millions, company would post below average annual Revenue growth of 21.69% year on year, if the fiscal year would end at Mar 31 2024.
A slow-down in the Mersana Therapeutics Inc 's Revenue growth from the 10.7% growth in Dec 31 2023.

Mersana Therapeutics inc achieved highest trailing twelve month year on year Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1 to 7.

Revenue TTM Q/Q Growth Statistics
High Average Low
61716.28 %
9652.67 %
-94.81 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 55
Healthcare Sector # 1
Overall # 7

Revenue TTM Y/Y Growth Statistics
High Average Low
61716.28 %
9652.67 %
-94.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 55
Sector # 112
S&P 500 # 418
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2024 period, Mersana Therapeutics Inc 's cumulative twelve months Revenue were $ 38 millions, company would post below average annual Revenue growth of -94.81% year on year, if the fiscal year would end at Mar 31 2024.
A slow-down in the Mersana Therapeutics Inc 's Revenue growth from the 10.7% growth in Dec 31 2023.

Mersana Therapeutics inc achieved highest trailing twelve month year on year Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1 to 7.

Revenue TTM Q/Q Growth Statistics
High Average Low
61716.28 %
9652.67 %
-94.81 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 55
Healthcare Sector # 1
Overall # 7

Revenue TTM Y/Y Growth Statistics
High Average Low
61716.28 %
9652.67 %
-94.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 55
Sector # 112
S&P 500 # 418




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MRSN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for MRSN's Competitors
Revenue Growth for Mersana Therapeutics Inc 's Suppliers
Revenue Growth for MRSN's Customers

You may also want to know
MRSN's Annual Growth Rates MRSN's Profitability Ratios MRSN's Asset Turnover Ratio MRSN's Dividend Growth
MRSN's Roe MRSN's Valuation Ratios MRSN's Financial Strength Ratios MRSN's Dividend Payout Ratio
MRSN's Roa MRSN's Inventory Turnover Ratio MRSN's Growth Rates MRSN's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Lifemd Inc 32.31%$ 32.307 millions
Maxcyte inc 32.25%$ 32.248 millions
Eton Pharmaceuticals Inc 32.11%$ 32.108 millions
Agile Therapeutics Inc32.07%$ 32.074 millions
Guardant Health Inc 30.90%$ 30.903 millions
Harrow Inc 30.38%$ 30.383 millions
Harmony Biosciences Holdings inc 29.38%$ 29.385 millions
Axonics Inc 29.16%$ 29.162 millions
Ani Pharmaceuticals Inc28.70%$ 28.697 millions
P3 Health Partners Inc 28.61%$ 28.606 millions
Exagen Inc 28.36%$ 28.362 millions
Viemed Healthcare Inc 27.90%$ 27.902 millions
Inspire Medical Systems inc 27.64%$ 27.644 millions
Sintx Technologies Inc 27.46%$ 27.458 millions
Amicus Therapeutics inc 27.32%$ 27.317 millions
Cvrx inc 27.27%$ 27.272 millions
Enovis Corp27.02%$ 27.021 millions
Eli Lilly And Company25.98%$ 25.977 millions
Optinose Inc 25.61%$ 25.612 millions
Twist Bioscience Corporation25.13%$ 25.128 millions
Vericel Corporation25.02%$ 25.024 millions
Pulmonx Corporation24.38%$ 24.376 millions
The Oncology Institute Inc 24.25%$ 24.247 millions
Dexcom Inc 24.19%$ 24.194 millions
The Pennant Group Inc 24.08%$ 24.079 millions
Lipella Pharmaceuticals Inc 23.58%$ 23.577 millions
Insulet Corporation23.35%$ 23.345 millions
Cadre Holdings inc 23.16%$ 23.159 millions
Lantheus Holdings Inc 22.96%$ 22.961 millions
Amphastar Pharmaceuticals Inc 22.72%$ 22.721 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com